title: [Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree].
abstract: OBJECTIVE
  To study efficacy and safety of a new dose and dosage form of proxodolol--a beta-adrenoblocker with alpha1-adrenoblocking activity--in patients with moderate arterial hypertension (AH).
  
  
  METHODS
  A total of 60 patients with verified diagnosis of essential AH of the second degree were randomized into two groups: group 1 (n=40) received proxodolol, group 2 (n=20) was given carvedilol. The trial lasted for 89 days.
  
  
  RESULTS
  The trial demonstrates that proxodolol is highly effective and safe in the treatment of AH.
  
  
  CONCLUSIONS
  Proxodolol is effective and safe in hypertension, in a dose 120 mg its activity is the same as carvedilol in a dose 25 mg.
authors.forename: S A
authors.initials: SA
authors.lastname: Beliaeva
mesh_terms: D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010069:Oxadiazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D012426:Russia; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D003692:Delayed-Action Preparations; D010069:Oxadiazoles; C088649:proxodolol